BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August

Day

• 1
• 2
• 3
• 4
• 5
• 7
• 8
• 9
• 10
• 11
• 12
• 14
• 15
• 16
• 17
• 18
• 19
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30

• Press Releases

  Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

  June 3, 2026

   · 

  4 min read
• Press Releases

  MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

  June 3, 2026

   · 

  6 min read
• Press Releases

  Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing

  June 3, 2026

   · 

  6 min read
• Press Releases

  Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation

  June 3, 2026

   · 

  5 min read
• Press Releases

  IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer

  June 3, 2026

   · 

  5 min read
• Press Releases

  Rezon Bio Appoints Dr. Ralf Otto as Chief Operating Officer to Support Next Phase of Growth and Operational Expansion

  June 3, 2026

   · 

  3 min read
• 

  CAR-T

  Legend soars on ‘best-in-class,’ ‘best-in-disease’ in vivo CAR T in early lymphoma study

  All six non-Hodgkin lymphoma patients on Legend Biotech’s CAR T therapy responded to treatment—findings that could make the biotech an attractive takeover target, according to analysts at Oppenheimer.

  June 3, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Deals

  Travere beefs up rare kidney disease portfolio with up to $1.1B China deal

  Travere Therapeutics will gain an exclusive license to the oral BTK inhibitor civorebrutinib, which analysts at Guggenheim Securities said could be “complementary” to the biotech’s IgA nephropathy drug Filspari.

  June 3, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Breast cancer

  Celcuity slides even after ‘practice-changing’ late-stage breast cancer data

  Celcuity’s gedatolisib doubled progression-free survival versus standard of care in certain patients with advanced breast cancer. Still, the biotech’s stock dropped more than 25% Tuesday.

  June 3, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

  June 3, 2026

   · 

  7 min read